Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Items 501–600 of 817
Several Noncontiguous Domains of CDK4 Are Involved in Binding to the P16 Tumor Suppressor Protein
Ceha, H. M., Nasser, I., Medema, R. H., & Slebos, R. J. C. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9183 · Cited by 14
Genetics, cellular biology and tumor microenvironment of melanoma
Ch’ng, S., & Tan, S. T. (2009) · Frontiers in bioscience · doi:10.2741/3286 · Cited by 19
Genomic analysis and clinical management of adolescent cutaneous melanoma
Rabbie, R., Rashid, M., Arance, A. M., Sánchez, M., Tell‐Martí, G., Potrony, M., Conill, C., van Doorn, R., Dentro, S. C., Gruis, N. A., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12574 · Cited by 14
“…mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene (Cannon-Albright et al., 1992), the cyclin-dependent kinase 4 (CDK4) gene (Zuo et al., 1996) and more recently in the Breast cancer 1 (BRCA1)-associated protein 1 (BAP1) (Aoude et al., 2013; Wiesner et al., 2011) and…”
BackgroundMC1R variant alleles and malignant melanoma risk in Israel
Galore-Haskel, G., Azizi, E., Mohamdi, H., Scope, A., Chaudru, V., Laitman, Y., Barak, F., Pavlotsky, F., Démenais, F., & Friedman, E. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.001 · Cited by 16
Synthesis and biological evaluation of guanidino analogues of roscovitine
Dolečková, I., Česnek, M., Dračínský, M., Brynda, J., Voller, J., Janeba, Z., & Kryštof, V. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.021 · Cited by 13
“Although mutations of CDKs have been described in some tumours (CDK4 [2,3], CDK6 [4], CDK9 [5]), more frequent is overexpression of cyclins or inactivation of endogenous CDK inhibitors [4,6].”
BackgroundPjanova, D., Molven, A., Akslen, L. A., Eņģele, L., Streinerte, B., Azarjana, K., & Heisele, O. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e3283287d3e · Cited by 13
Drug Targeting of Oncogenic Pathways in Melanoma
Fecher, L. A., Amaravadi, R. K., Schuchter, L. M., & Flaherty, K. T. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.004 · Cited by 14
Pissa, M., Helkkula, T., Appelqvist, F., Silander, G., Borg, Å., Pettersson, J., Lapins, J., Nielsen, K., Höiom, V., & Helgadóttir, H. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1914346 · Cited by 14
Role of the Cyclin-Dependent Kinase Inhibitor CDKN2A in Familial Melanoma
Hogg, D., Brill, H., Liu, L., Monzon, J. G., Summers, A. M., From, L., & Lassam, N. J. (1998) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/120347549800200312 · Cited by 13
Disorders of the Cutaneous Melanocyte
MacKie, R. M. (2004) · Wiley eBooks · doi:10.1002/9780470750520.ch38 · Cited by 13
Sargen, M. R., Pfeiffer, R. M., Yang, X. R., Tucker, M. A., & Goldstein, A. M. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.06.138 · Cited by 12
“(Bishop et al., 2002, Puntervoll et al., 2013, Soufir et al., 1998, Zuo et al., 1996) In this study, we assessed differences in the anatomic distribution of melanomas between mutation carriers (CDKN2A, CDK4) and those without a mutation in either gene (non-carriers) from U.S. melanoma-prone…”
BackgroundSelf-citationInvolvement of ANXA5 and ILKAP in Susceptibility to Malignant Melanoma
Arroyo-Berdugo, Y., Alonso, S., Ribas, G., Ibarrola‐Villava, M., Peña-Chilet, M., Martínez‐Cadenas, C., Gardeazábal, J., Ratón, J. A., Sánchez-Díez, A., Careaga, J. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095522 · Cited by 12
“Mutations in CDK4 are rare and worldwide only three families have been reported to carry mutations on this gene worldwide [10,11].”
BackgroundTruncating mutations of TP53AIP1 gene predispose to cutaneous melanoma
Benfodda, M., Gazal, S., Descamps, V., Basset‐Séguin, N., Deschamps, L., Thomas, L., Lebbé, C., Saïag, P., Zanetti, R., Sacchetto, L., et al. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22528 · Cited by 13
“CDK4 is an oncogene negatively controlled by P16INKA, one of the CDKN2A locus products, and is mutated in <1% of melanoma families.(11,12) Six years ago, a third gene, BAP1was reported as a predisposing factor to ocular melanoma, melanocytic neoplasms, mesothelioma, and renal carcinoma.”
BackgroundMultiplex melanoma families are enriched for polygenic risk
Law, M. H., Aoude, L. G., Duffy, D. L., Long, G. V., Johansson, P. A., Pritchard, A. L., Khosrotehrani, K., Mann, G. J., Montgomery, G. W., Iles, M. M., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa156 · Cited by 13
“This variant, first described in 1994 (27), is one of the most frequently reported deleterious founder missense variants reported in CDKN2A (28) and results in impaired binding of p16 to CDK4 (29).”
Self-citationLluria-Prevatt, M., Dickinson, S. E., & Alberts, D. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_13 · Cited by 13
Ng, D., Yang, X. R., Tucker, M. A., & Goldstein, A. M. (2008) · BMC Research Notes · doi:10.1186/1756-0500-1-86 · Cited by 12
“Mutations in CDKN2A account for 20–40% of CMM kindreds [2], while CDK4 mutations have been identified in < 10 CMM families [3-6].”
BackgroundSelf-citationNovel CDKN2A mutations in Austrian melanoma patients
Burgstaller-Muehlbacher, S., Marko, M., Müller, C., Wendt, J., Pehamberger, H., & Okamoto, I. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000179 · Cited by 13
Sargent, L. M., Nelson, M. A., Lowry, D. T., Senft, J. R., Jefferson, A. M., Ariza, M. E., & Reynolds, S. H. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1162 · Cited by 12
“Germline mutations in the CDK4 region of chromosome arm 12q have been reported in familial melanoma (Zuo et al., 1996).”
BackgroundMarian, C., Scope, A., Laud, K., Friedman, E., Pavlotsky, F., Yakobson, E., Paillerets, B. B., & Azizi, E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602629 · Cited by 14
“Germline mutations in CDK4 were detected in three melanoma families (Zuo et al, 1996; Soufir et al, 1998).”
BackgroundStructural Basis for the Modulation of CDK-Dependent/Independent Activity of Cyclin D1
Ferrer, J.-L., Dupuy, J., Borel, F., Jacquamet, L., Noel, J. P., & Dulić, V. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3506 · Cited by 13
Nagore, J. C. E. (2000) · Acta Dermato Venereologica · doi:10.1080/000155500300012936 · Cited by 13
“The recent identi® cation of germline mutations within the exon 2 of CDK4 gene on chromosome 12q15 in 2 families suggests that this may be another candidate gene for predisposing to a few familial malignant melanomas (6, 9).”
BackgroundAML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia
Barton, K., & Nucifora, G. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200003)22:3<214::aid-bies2>3.0.co;2-i · Cited by 20
Melanoma — Epidemiology, Genetics and Risk Factors
John, A., Jarrett, S. G., Marsch, A. F., Lagrew, J. P., & Cleary, L. C. (2013) · InTech eBooks · doi:10.5772/55172 · Cited by 17
“By binding to and inhibiting CDK4, p16 acts to prevent cell cycle progression, and when p16 function is lost, cells lose regulatory control over CDK/cyclin activity and proceed into unregulated cell division (Bartkova et al., 1996; Chin et al., 1998; Liggett and Sidransky, 1998).”
BackgroundInfluentialCozzolino, A. M., Pedace, L., Castori, M., Simone, P. D., Preziosi, N., Sperduti, I., Panetta, C., Mogini, V., Bernardo, C. D., Morrone, A., et al. (2011) · Familial Cancer · doi:10.1007/s10689-011-9502-6 · Cited by 11
“A much smaller number of families share heterozygous mutations in CDK4 [7].”
BackgroundVitiligo: a review of the pathogenesis
Choi, D., Isedeh, P. N., & Hamzavi, I. H. (2014) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000450307.76457.a3 · Cited by 11
Innes, J., Reali, L., Clayton‐Smith, J., Hall, G., Lim, D., Burghel, G. J., French, K., Khan, U., Walker, D., Lalloo, F. I., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104892 · Cited by 11
Brotherton, D. H., Dhanaraj, V., Wick, S. T., Brizuela, L., Domaille, P. J., Volyanik, E., Xu, X., Parisini, E., Smith, B. O., Archer, S. J., et al. (1998) · Nature · doi:10.1038/24657 · Cited by 14
The Western Australian Melanoma Health Study: Study design and participant characteristics
Ward, S. V., Cadby, G., Lee, A. J., Cole, J. M., Heyworth, J. S., Millward, M., Wood, F. M., & Palmer, L. J. (2011) · Cancer Epidemiology · doi:10.1016/j.canep.2011.02.010 · Cited by 12
“Three high-penetrance melanoma-susceptibility genes have been identified: cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase 4 (CDK4) and a locus on 1p22 [24–27].”
BackgroundSteitz, J., Büchs, S., Tormo, D., Ferrer, A., Wenzel, J., Huber, C., Wölfel, T., Barbacid, M., Malumbres, M., & Tüting, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21349 · Cited by 11
“This oncogenic mutation was identified with melanoma-specific cytolytic T cells(11) and could also be found in the germline of some families with hereditary melanoma.(12) Introduction of the cdk4 R24C mutation into the germline of mice favours the development of cutaneous melanocytic tumours following carcinogen-treat…”
BackgroundVignoli, M., Scaini, M. C., Ghiorzo, P., Sestini, R., Bruno, W., Menin, C., Gensini, F., Piazzini, M., Testori, A., Manoukian, S., et al. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328319412f · Cited by 11
Nagore, E., Montoro, A., Oltra, S., Ledesma, E., Estrada, R. B., n, J. M. M., Oliver, V., Fortea, J. M., & n, C. G. (2005) · Melanoma Research · doi:10.1097/00008390-200512000-00012 · Cited by 11
Molecular Biology of Malignant Melanoma
Pons, M., Mancheño‐Corvo, P., Martín‐Duque, P., & Quintanilla, M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77574-6_20 · Cited by 13
Lavernia, J., Claramunt, R., Romero, I., López‐Guerrero, J. A., Llombart-Bosch, A., & Machado, I. (2024) · Cancers · doi:10.3390/cancers16020432 · Cited by 13
“1 (Figure 1), and proximal to MDM2 , located [60–62].”
BackgroundTrappey, A., Fernando, A., Gaur, R. L., Raj, M. H. G., & Ouhtit, A. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s42 · Cited by 11
“A CDK4 mutation has been found in melanoma prone families (53, 54) and produces a mutated protein with oncogenec activity; this protein interferes with the binding of the CDK4 protein to p16, preventing inhibition of its enzymatic activity, thereby leading to unchecked cellular division (55) (59 I think this is 49 and…”
BackgroundManagement of Melanoma Families
Bergman, W., & Gruis, N. A. (2010) · Cancers · doi:10.3390/cancers2020549 · Cited by 12
“The mutations restrict themselves so far to two missense mutations at codon 24 in exon 2 of the CDK4 gene resulting in amino acid changes Arg24Cys and Arg24His [89,90].”
BackgroundImmortalization of primary marmoset skin fibroblasts by CRISPR-Cas9-mediated gene targeting
Jeong, Y.-J., Cho, J., Kwak, J., Sung, Y. H., & Kang, B.-C. (2022) · Animal Cells and Systems · doi:10.1080/19768354.2022.2151509 · Cited by 11
“melanoma and abolishes the ability of CDK4 protein to bind p16 protein (Wolfel et al. 1995; Zuo et al. 1996).”
BackgroundEpidemiology of Malignant Melanoma
Whiteman, D. C., & Green, A. C. (2010) · Springer eBooks · doi:10.1007/978-3-642-05072-5_2 · Cited by 14
Jäger, E., & Knuth, A. K. (2012) · Europe PMC (PubMed Central) · doi:10.5167/uzh-75664 · Cited by 10
NEK11 as a candidate high-penetrance melanoma susceptibility gene
Christodoulou, E., van Doorn, R., Visser, M., Teunisse, A. F. A. S., Versluis, M., van der Velden, P., Hayward, N. K., Jochemsen, A. G., & Gruis, N. A. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106134 · Cited by 12
Self-citationMarzo, N., Ortega, S., Stratmann, T., García, A., Ríos, M., Giménez, A., Gomis, R., & Mora, C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.1189 · Cited by 11
“This mutation prevents the binding of the inhibitors of Cdk4 protein family to Cdk4 (7, 11, 12, 13), leading to Cdk4 hyperactivity.”
BackgroundEstimating the relative risk of developing melanoma in INK4A carriers
Berwick, M., Orlow, I., Mahabir, S., Myskowski, P. L., Coit, D. G., Brady, M. S., Roy, P., Song, Y., Canchola, R., Barz, A., et al. (2004) · European Journal of Cancer Prevention · doi:10.1097/00008469-200402000-00010 · Cited by 10
“With the exception of four families identified so far with germline mutations in cyclindependent kinase 4, CDK4 (Zuo et al., 1996; Soufir et al., 1998; Holland et al., 1999), INK4A is the only inherited gene identified to date that is associated with suscept-”
BackgroundInfluentialImmunological detection of altered signaling molecules involved in melanoma development
Kawakami, Y., Sumimoto, H., Fujita, T., & Matsuzaki, Y. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1583-y · Cited by 10
“The same germ line mutation in CDK4 was found in multiple melanoma prone families [30,31].”
BackgroundUdayakumar, D., & Tsao, H. (2009) · Genome Medicine · doi:10.1186/gm95 · Cited by 10
“Subsequently, Zuo and colleagues [7] identified heritable alterations in the CDK4 gene in a few families that lacked germline CDKN2A mutations.”
BackgroundOzola, A., Azarjana, K., Doniņa, S., Proboka, G., Mandrika, I., Petrovska, R., Čēma, I., Heisele, O., Eņģele, L., Streinerte, B., et al. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.01.002 · Cited by 11
“1, OMIM 123829) (6), have been associated with high penetrance melanoma susceptibility.”
BackgroundNielsen, E.-M. D., Hansen, L., Stissing, T., Yanagisawa, K., Borch‐Johnsen, K., Poulsen, P., Vaag, A. A., Hansen, T. F., & Pedersen, O. B. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0647-3 · Cited by 11
Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance
Zheng, C., & Sarin, K. Y. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100837 · Cited by 22
Dermal Drug Delivery for Cutaneous Malignancies: Literature at a Glance
Gupta, V., & Trivedi, P. (2015) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-015-9236-3 · Cited by 10
“They have identified a region on the short arm of chromosome 9 associated with melanoma which was also absent in cancer cell lines [70, 71].”
BackgroundFactors influencing and modifying the decision to pursue genetic testing for skin cancer risk
Fogel, A. L., Jaju, P. D., Li, S., Halpern‐Felsher, B. L., Tang, J. Y., & Sarin, K. Y. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.050 · Cited by 9
Ponizovskiy, M. R. (2013) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2013005686 · Cited by 12
Familial Risk Of Melanoma and Links with Other Cancers
Lee, K. C., Higgins, H. W., & Qureshi, A. A. (2015) · Melanoma Management · doi:10.2217/mmt.14.34 · Cited by 12
Bergh, G., Telleus, A., Fritzon, A., Kornfält, S., Johnson, E., Olsson, I., & Gullberg, U. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00743-3 · Cited by 9
Absence of R24C Mutation of the CDK4 Gene in Leukemias and Solid Tumors
Mori, N., Yang, R., Kawamata, N., Miller, C. W., Mizoguchi, H., & Koeffler, H. P. (2003) · International Journal of Hematology · doi:10.1007/bf02983783 · Cited by 9
“It was also detected as a germline mutation in 2 unrelated families with melanoma [ 3 ].”
BackgroundLu, X., Yi, H., Xu, J.-L., Sun, Y., Li, J., Cao, S., & Xu, Q. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.8.0005 · Cited by 12
“CDK4, but not CDK6, is strongly involved in the development of melanoma (Zuo et al 1996), while CDK6 activity is remarkably elevated in squamous cell carcinomas, without alteration of CDK4 activity (Timmermann et al 1997).”
BackgroundPritchard‐Jones, K. (1996) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011578 · Cited by 9
Effect of long-wave UV radiation on mouse melanoma: an in vitro and in vivo study
Pastila, R. K. (2006) · Helda - University of Helsinki Institutional Repository · Cited by 10
Lukas, C., Jensen, S. S., Bártková, J., Lukas, J., & Bartek, J. J. (1999) · Hybridoma · doi:10.1089/027245799315871 · Cited by 9
Role of Molecular Biology in Diagnostic Pathology of Melanoma
Slominski, A. T., Carlson, J. A., Wortsman, J., & Mihm, M. C. (2003) · Humana Press eBooks · doi:10.1385/1-59259-145-0:123 · Cited by 9
Li, M., Maddison, L. A., Crees, Z. D., & Chen, W. (2013) · Zebrafish · doi:10.1089/zeb.2012.0816 · Cited by 9
“28 A mutant CDK4 found in human cancers, CDK4 R24C , promotes tumorigenesis because it is insensitive to INK4 CKIs, 29,30 the principal negative regulators of CDK4.”
Karagianni, F., Njauw, C.-N. J., Kypreou, K. P., Stergiopoulou, A., Plaka, M., Polydorou, D., Chasapi, V., Pappas, L., Stratigos, I. A., Champsas, G., et al. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2969 · Cited by 8
“All variants occur in codon 24, with families either carrying a p.R24C substitution (13) or a p.R24H substitution (12).”
Murphy, J. M., Jeong, K., Ahn, E.-Y. E., & Lim, S. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102013 · Cited by 8
Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers—An Overview
Mathiyalagan, R., Valappil, A. K., Yang, D., Kang, S. C., & Thambi, T. (2022) · Gels · doi:10.3390/gels8090560 · Cited by 9
Common Marmoset Cell Lines and Their Applications in Biomedical Research
Олеговна, Б. Е., Сергеевна, Ж. А., Avdoshina, D., Kupriyanova, N., Kolyako, Y. V., Kostyushev, D. S., & Gordeychuk, I. V. (2023) · Cells · doi:10.3390/cells12162020 · Cited by 9
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics
Bronchud, M. H., Brizuela, L., Gyuris, J., & Mansuri, M. M. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-664-5_11 · Cited by 8
Consequences of Antigen Self-Presentation by Tumor-Specific Cytotoxic T Cells
Staege, M. S., Schneider, J., Eulitz, M., Scholz, S., Bornkamm, G. W., Wölfel, T., & Reske‐Kunz, A. B. (2000) · Immunobiology · doi:10.1016/s0171-2985(00)80088-1 · Cited by 8
Höiom, V., Tuominen, R., & Hansson, J. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20931 · Cited by 8
“There have also been a few reported cases of activating mutations in the CDK4 gene in other populations (Zuo et al., 1996; Soufir et al., 1998; Tsao et al., 1998; Molven et al., 2005) and linkage evidence of another putative susceptibility gene at 1p22 has been reported (Gillanders et al.”
BackgroundCardinale, A., Cantalupo, S., Lasorsa, V. A., Montella, A., Cimmino, F., Succoio, M., Vermeulen, M., Baltissen, M. P. A., Esposito, M., Avitabile, M., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab293 · Cited by 8
Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families
Perić, B., Cerkovnik, P., Novaković, S., Žgajnar, J., Bešič, N., & Hočevar, M. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-86 · Cited by 10
“Exons 1α, 1β, 2 and 3, including part of promoter region and 3'-UTR region of the CDKN2A gene, exon 2 of the CDK4 gene and the coding sequence of the MC1R gene were amplified by polymerase chain reaction (PCR) as described previously [12-14].”
The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired
Becker, T. M., Ayub, A. L. P., Kefford, R. F., Mann, G. J., & Rizos, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21265 · Cited by 9
No evidence of a role for activating CDK2 mutations in melanoma
Walker, G. J., & Hayward, N. K. (2001) · Melanoma Research · doi:10.1097/00008390-200108000-00004 · Cited by 8
Self-citationBreast cancer genetics and managed care
Kutner, S. E. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8+ · Cited by 1
Sargen, M. R., Pfeiffer, R. M., Elder, D. E., Yang, X. R., Goldstein, A. M., & Tucker, M. A. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1521 · Cited by 8
“Similar findings (P 0.05) were observed for familial cases with and without CDKN2A and CDK4 mutations (Fig.”
BackgroundInfluentialSelf-citationDeletion of the MGMT gene in familial melanoma
Appelqvist, F., Yhr, M., Erlandson, A., Martinsson, T., & Enerbäck, C. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22180 · Cited by 7
“CDK4 has been linked to FM in 17 families worldwide (Zuo et al., 1996; Soufir et al., 1998; Molven et al., 2005; Puntervoll et al., 2013), which makes it a very rare cause of FM. CDKN2A could be linked to 20–40% of all FM cases in the world, but the prevalence is generally low in Sweden and…”
BackgroundInfluentialThe HGF/SF Mouse Model of UV-Induced Melanoma as an In Vivo Sensor for Metastasis-Regulating Gene
Leonard, M. K., Pamidimukkala, N., Puts, G. S., Snyder, D. E., Slominski, A. T., & Kaetzel, D. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081647 · Cited by 8
Aktary, Z., McMahon, M., & Larue, L. (2017) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_32-1 · Cited by 9
Longitudinal Genomic Evolution of Conventional Papillary Thyroid Cancer With Brain Metastasis
Luo, H., Liao, X. P., Qin, Y., Hou, Q., Xue, Z., Liu, Y., Shen, F., Wang, Y., Jiang, Y., Song, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620924 · Cited by 7
Hogg, D., Liu, L., & Lassam, N. J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-145-0:109 · Cited by 7
“Investigators have described three families that bear germline coding mutations in the CDK4 gene (chromosome 12q14) and are identical in clinical presentation to kindreds that bear CDKN2A mutations (34,35).”
BackgroundRecent Developments in Targeting the Cell Cycle in Melanoma
Hung, C., Nguyen, T. T. T., Poulikakos, P. I., & Polsky, D. (2025) · Cancers · doi:10.3390/cancers17081291 · Cited by 7
“The R24C mutation prevents p16INK4A from binding to CDK4, allowing for The germline CDK4 R24C mutation is also found in mela-noma-prone families, albeit rarely. uninhibited cell cycle progression through RB phosphorylation by Cyclin D–CDK4 complexes [27].”
Molecular genetic markers of pigmented skin melanoma (literature review)
Eremina, E. N., Karakhanyan, A. R., Александрович, В. Д., Титов, К. С., & Zukov, R. A. (2020) · Siberian medical review · doi:10.20333/2500136-2020-3-38-46 · Cited by 6
“Выявлена прямая связь между герминальными мутациями CDKN2A и риском возникновения рака поджелудочной железы [38].”
New Insights into Melanoma Tumor Syndromes
Rashid, S., Gupta, S., McCormick, S. R., & Tsao, H. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100152 · Cited by 7
“All sequence variants of CDK4 have been described to occur in exon 2, which is the site of the p16:CDK4 interaction; mutagenesis of this site abrogates p16 binding (Rossi et al., 2019; Zuo et al., 1996).”
BackgroundFraser, M. C., Goldstein, A. M., & Tucker, M. A. (1997) · Seminars in Oncology Nursing · doi:10.1016/s0749-2081(97)80007-1 · Cited by 6
Self-citationVisser, M., van der Stoep, N., & Gruis, N. A. (2019) · Familial Cancer · doi:10.1007/s10689-018-00115-3 · Cited by 8
Novedades en genética del melanoma
Puig, S., Puig‐Butillé, J. A., Bádenas, C., Cuéllar, F., & Malvehy, J. (2006) · Piel · doi:10.1016/s0213-9251(06)72488-1 · Cited by 6
Modeling Inheritance of Malignant Melanoma With DNA Markers in Sinclair Swine
Gomez‐Raya, L., Okomo‐Adhiambo, M., Beattie, C. W., Osborne, K., Rink, A., & Rauw, W. M. (2007) · Genetics · doi:10.1534/genetics.106.070268 · Cited by 7
Modeling Cell Cycle Control and Cancer with pRB Tumor Suppressor
Yamasaki, L. (2006) · Springer eBooks · doi:10.1007/b136682 · Cited by 7
Molecular genetics of pancreatic carcinoma
Kern, S. E., Schutte, S., Hahn, S. A., Caldas, C., Redston, M. S., & Seymour, A. B. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(96)85216-2 · Cited by 6
Copy number variations in malignant melanoma: genomic regions, biomarkers, and therapeutic targets
Lukáčová, E., Pös, O., Turyova, E., Hurtová, T., Hanzlíková, Z., Szemes, T., & Burjanivová, T. (2024) · Neoplasma · doi:10.4149/neo_2024_240207n58 · Cited by 5
Impacto del diagnóstico de melanoma sobre la fotoprotección
Moyano, E. G., de Ramón, E., Martínez-García, S., Gómez, R., Crespo-Erchiga, V., Crespo, A., & Ojeda, A. (2010) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2009.12.022 · Cited by 5
Chatterjee, S., Chakraborty, R., & Hasija, Y. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1950571 · Cited by 5
“CDK4 is the second gene found to be associated with high-risk melanoma (Zuo et al., 1996).”
BackgroundDefining novel causal SNPs and linked phenotypes at melanoma-associated loci
Castañeda-García, C., Iyer, V., Nsengimana, J., Trower, A. J., Droop, A., Brown, K. M., Choi, J., Zhang, T., Harland, M., Newton‐Bishop, J., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac074 · Cited by 5
“High-penetrance genetic variants in genes such as cyclin-dependent kinase inhibitor 2A (CDKN2A) (6), cyclin-dependent kinase 4 (CDK4) (7), telomerase reverse transcriptase (TERT) (8), protection of telomeres 1 (POT1) (9,10) and other telomere-associated genes are found in approximately half of melanoma-prone families…”
BackgroundLoo, J. C. Y., Paterson, A. D., Hao, A., Shennan, M., Peretz, H., Sidi, Y., Hogg, D., & Yakobson, E. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.027300 · Cited by 6
Todd (2009) · International Journal of Oncology · doi:10.3892/ijo_00000349 · Cited by 5
“Analysis of cyclin D and its kinase partners, CDK4 and CDK6 did not reveal abnormalities in expression nor, in the case of CDK4, did we find mutations that have been reported to inhibit p16 binding in NIH-OVCAR-3 cells (7,28,29).”
BackgroundMolecular Analysis of Structural Abnormalities in Papillary Thyroid Carcinoma Genome
Васильев, Е. В., Rumyantsev, P. O., Saenko, V., Ильин, А. А., Polyakova, E. Y., Nemtsova, M. V., & Zaletaev, D. V. (2004) · Molecular Biology · doi:10.1023/b:mbil.0000037006.90193.f6 · Cited by 5
Gray‐Schopfer, V. C., & Bennett, D. C. (2006) · Wiley eBooks · doi:10.1002/9780470987100.ch24 · Cited by 6
Halaban, R., & Moellmann, G. E. (2006) · Wiley eBooks · doi:10.1002/9780470987100.ch22 · Cited by 5
A population-based study on the familial aggregation of cutaneous malignant melanoma in Iceland
Eldon, B., Thorlacius, S., Jónsson, Þ., Jonasson, J. G., Kjartansson, J., Bödvarsson, S., Steingrímsson, E., & Rafnar, Þ. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.029 · Cited by 7
Familial Melanoma Genes, Melanocyte Immortalization, and Melanoma Initiation
Bennett, D. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-994-3_10 · Cited by 5
ATM , ATR and Mre11 complex genes in hereditary susceptibility to breast cancer
Pylkäs, K. (2007) · Cited by 5
Molecular Genetics of Pancreatic Carcinoma
Moskaluk, C. A., & Kern, S. E. (1998) · Humana Press eBooks · doi:10.1007/978-1-4612-1810-4_1 · Cited by 5
A novel L94Q mutation in the CDKN2A gene in a melanoma kindred
Stefanija, M. A., evar, M. H., Podkrajšek, K. T., Kr??i??nik, C., & Battelino, T. (2003) · Melanoma Research · doi:10.1097/00008390-200312000-00005 · Cited by 5
Yeap, I., Becker, T. M., Azimi, F., & Kernohan, M. (2022) · Australasian Journal of Plastic Surgery · doi:10.34239/ajops.v5n2.324 · Cited by 5
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.